AZD2461: Next-Generation PARP Inhibitor for Breast Cancer Research

Executive Summary: AZD2461 is a potent poly (ADP-ribose) polymerase (PARP) inhibitor with an IC50 of 5 nM in biochemical assays, selectively targeting PARP-1 to induce G2 phase cell cycle arrest in human breast cancer cells (Schwartz 2022). It reduces viable cell numbers in MCF-7 and SKBR-3 cell lines in a concentration- and time-dependent manner. AZD2461 exhibits low affinity for P-glycoprotein (Pgp), helping overcome Pgp-mediated resistance (APExBIO). In vivo, it extends relapse-free survival in BRCA1-mutated tumor models. The compound is supplied by APExBIO as SKU A4164 (product page).

Biological Rationale

Poly (ADP-ribose) polymerase (PARP) enzymes are essential for single-strand DNA break repair via the base excision repair pathway (Schwartz 2022). Inhibition of PARP in cancer cells with deficient homologous recombination (e.g., BRCA1/2 mutations) results in synthetic lethality. This mechanism underpins the therapeutic value of PARP inhibitors in breast cancer research. Drug resistance mediated by efflux pumps such as P-glycoprotein (Pgp) is a significant challenge in this context. AZD2461 was designed with reduced Pgp affinity to address this limitation, enabling more effective modulation of the DNA repair pathway in resistant tumor types (APExBIO).

Mechanism of Action of AZD2461

AZD2461 inhibits PARP-1 enzymatic activity with a biochemical IC50 of 5 nM. In cultured breast cancer cells such as MCF-7 and SKBR-3, AZD2461 triggers cell cycle arrest, increasing the percentage of cells in the G2 phase and reducing the S phase fraction. This arrest correlates with reduced cell viability and increased cytotoxicity in a dose- and time-dependent fashion, typically observed at concentrations between 5 and 50 μM with incubation times of 48–72 hours. Mechanistically, PARP inhibition impairs DNA repair, resulting in the accumulation of DNA damage and subsequent cell death—particularly in cells with deficient homologous recombination repair (Schwartz 2022).

Evidence & Benchmarks

• AZD2461 inhibits PARP-1 with an IC50 of 5 nM in biochemical assays (APExBIO).
• In MCF-7 and SKBR-3 cells, AZD2461 reduces viable cell numbers in a concentration- and time-dependent manner (5–50 μM; 48–72 h) (Schwartz 2022).
• Cell cycle analysis reveals G2 phase arrest and reduction in S phase upon AZD2461 treatment (Schwartz 2022).
• In vivo, AZD2461 inhibits PARP activity in KB1P mouse tumor models, with PAR levels returning to baseline after 24 hours (Schwartz 2022).
• AZD2461 demonstrates lower affinity for Pgp than olaparib, reducing susceptibility to Pgp-mediated drug resistance (APExBIO).
• Long-term administration is well tolerated and significantly extends relapse-free survival in BRCA1-mutated tumor models (Schwartz 2022).

For a practical perspective on troubleshooting and advanced protocol integration, see this guide, which AZD2461’s product dossier expands by providing updated in vivo efficacy metrics and Pgp-affinity data.

Applications, Limits & Misconceptions

AZD2461 is widely used in preclinical studies of breast cancer, particularly in genetically defined models such as BRCA1/2-mutated lines. It is suitable for dissecting DNA repair dependencies and testing strategies to overcome drug resistance. However, certain boundaries must be recognized for reproducible results.

Common Pitfalls or Misconceptions

• AZD2461 is not water-soluble; use DMSO (≥16.35 mg/mL) or ethanol with ultrasonic assistance (≥45.2 mg/mL) for stock solutions (APExBIO).
• PARP inhibition is cytotoxic primarily in homologous recombination-deficient cells; effect is less pronounced in wild-type backgrounds.
• In vivo efficacy can be reduced by improper formulation or dosing outside validated ranges (5–50 μM for cell culture).
• PAR levels recover to baseline within 24 hours post-dosing; sustained inhibition requires repeated administration (Schwartz 2022).
• AZD2461’s reduced Pgp affinity does not eliminate all resistance mechanisms; other efflux or repair pathways may compensate.

For a scenario-driven protocol optimization, consult this article. The present dossier clarifies product handling and mechanistic benchmarks not detailed in that workflow guide.

Workflow Integration & Parameters

AZD2461 (SKU A4164) is supplied as a solid by APExBIO. Prepare stock solutions in DMSO or ethanol. Store at -20°C. Use freshly prepared solutions for best results; extended storage of working solutions is not recommended. Typical cell culture concentrations are 5–50 μM, with 48–72 hour incubation. Monitor cell cycle distribution and viability to assess efficacy. In vivo protocols require formulation to maintain plasma exposure and repeated dosing for sustained PARP inhibition.

To extend findings on protocol troubleshooting and advanced PARP signaling pathway analysis, compare with this resource, which this dossier updates with new solubility and tolerance data.

Conclusion & Outlook

AZD2461 advances poly (ADP-ribose) polymerase inhibition research, providing robust cytotoxicity in BRCA1-mutated and Pgp-expressing breast cancer models. Its low Pgp affinity and well-characterized pharmacodynamics enable studies of relapse-free survival extension. For comprehensive product specifications and ordering, visit the official AZD2461 product page. Ongoing research is clarifying its potential in combination regimens and other DNA repair-deficient cancers.